Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Eli Lilly and Co. is expanding its real estate footprint in Boston’s Seaport district with a new lease for 75,000 square feet ...